-
Something wrong with this record ?
CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8+ T-cell Responses
Y. Liu, MA. Cuendet, L. Goffin, R. Šachl, M. Cebecauer, L. Cariolato, P. Guillaume, P. Reichenbach, M. Irving, G. Coukos, IF. Luescher,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Lymphocyte Activation immunology MeSH
- CD8 Antigens chemistry genetics metabolism MeSH
- Models, Biological MeSH
- CD8-Positive T-Lymphocytes immunology metabolism MeSH
- Histocompatibility Antigens chemistry genetics immunology MeSH
- Protein Interaction Domains and Motifs MeSH
- Protein Conformation MeSH
- Models, Molecular MeSH
- Multiprotein Complexes chemistry immunology metabolism MeSH
- Mutation MeSH
- Mice, Knockout MeSH
- Mice MeSH
- Peptides chemistry immunology metabolism MeSH
- Amino Acid Sequence MeSH
- Protein Binding MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The coreceptor CD8αβ can greatly promote activation of T cells by strengthening T-cell receptor (TCR) binding to cognate peptide-MHC complexes (pMHC) on antigen presenting cells and by bringing p56Lck to TCR/CD3. Here, we demonstrate that CD8 can also bind to pMHC on the T cell (in cis) and that this inhibits their activation. Using molecular modeling, fluorescence resonance energy transfer experiments on living cells, biochemical and mutational analysis, we show that CD8 binding to pMHC in cis involves a different docking mode and is regulated by posttranslational modifications including a membrane-distal interchain disulfide bond and negatively charged O-linked glycans near positively charged sequences on the CD8β stalk. These modifications distort the stalk, thus favoring CD8 binding to pMHC in cis. Differential binding of CD8 to pMHC in cis or trans is a means to regulate CD8+ T-cell responses and provides new translational opportunities.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023349
- 003
- CZ-PrNML
- 005
- 20201214125822.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jmb.2019.10.019 $2 doi
- 035 __
- $a (PubMed)31704286
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Liu, Yang $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 245 10
- $a CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8+ T-cell Responses / $c Y. Liu, MA. Cuendet, L. Goffin, R. Šachl, M. Cebecauer, L. Cariolato, P. Guillaume, P. Reichenbach, M. Irving, G. Coukos, IF. Luescher,
- 520 9_
- $a The coreceptor CD8αβ can greatly promote activation of T cells by strengthening T-cell receptor (TCR) binding to cognate peptide-MHC complexes (pMHC) on antigen presenting cells and by bringing p56Lck to TCR/CD3. Here, we demonstrate that CD8 can also bind to pMHC on the T cell (in cis) and that this inhibits their activation. Using molecular modeling, fluorescence resonance energy transfer experiments on living cells, biochemical and mutational analysis, we show that CD8 binding to pMHC in cis involves a different docking mode and is regulated by posttranslational modifications including a membrane-distal interchain disulfide bond and negatively charged O-linked glycans near positively charged sequences on the CD8β stalk. These modifications distort the stalk, thus favoring CD8 binding to pMHC in cis. Differential binding of CD8 to pMHC in cis or trans is a means to regulate CD8+ T-cell responses and provides new translational opportunities.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigeny CD8 $x chemie $x genetika $x metabolismus $7 D016827
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x imunologie $x metabolismus $7 D018414
- 650 _2
- $a histokompatibilní antigeny $x chemie $x genetika $x imunologie $7 D006649
- 650 _2
- $a aktivace lymfocytů $x imunologie $7 D008213
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši knockoutované $7 D018345
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a multiproteinové komplexy $x chemie $x imunologie $x metabolismus $7 D046912
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a peptidy $x chemie $x imunologie $x metabolismus $7 D010455
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a interakční proteinové domény a motivy $7 D054730
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cuendet, Michel A $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland; Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, USA.
- 700 1_
- $a Goffin, Laurence $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Šachl, Radek $u Department of Biophysical Chemistry, J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences, 18223 Prague, Czech Republic.
- 700 1_
- $a Cebecauer, Marek $u Department of Biophysical Chemistry, J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences, 18223 Prague, Czech Republic.
- 700 1_
- $a Cariolato, Luca $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Guillaume, Philippe $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Reichenbach, Patrick $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Irving, Melita $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Coukos, George $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland.
- 700 1_
- $a Luescher, Immanuel F $u Ludwig Institute for Cancer Research, University of Lausanne, and Department of Oncology, University Hospital of Lausanne, 1009, Lausanne, Switzerland. Electronic address: immanuel.luescher@unil.ch.
- 773 0_
- $w MED00002808 $t Journal of molecular biology $x 1089-8638 $g Roč. 431, č. 24 (2019), s. 4941-4958
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31704286 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125821 $b ABA008
- 999 __
- $a ok $b bmc $g 1595668 $s 1114025
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 431 $c 24 $d 4941-4958 $e 20191105 $i 1089-8638 $m Journal of Molecular Biology $n J Mol Biol $x MED00002808
- LZP __
- $a Pubmed-20201125